Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

BACKGROUND: Continuous treatment is recommended for patients with moderate‐to‐severe psoriasis; however, treatment may need to be interrupted in routine clinical practice. OBJECTIVE: To assess outcomes in patients continuously treated with ixekizumab versus those who interrupted therapy and were sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, A., Papp, K.A., Sofen, H., Augustin, M., Yosipovitch, G., Katoh, N., Mrowietz, U., Ohtsuki, M., Poulin, Y., Shrom, D., Burge, R., See, K., Mallbris, L., Gordon, K.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485049/
https://www.ncbi.nlm.nih.gov/pubmed/28190255
http://dx.doi.org/10.1111/jdv.14163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485049/
https://www.ncbi.nlm.nih.gov/pubmed/28190255
http://dx.doi.org/10.1111/jdv.14163

Ejemplares similares